AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19720489
Drug: Double-dose gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-dose gadobutrol
Trial: 19720489
Drug: Single-dose gadobenate-dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose gadobenate-dimeglumine
Trial: 16568409
Drug: Weight training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight training (twice-weekly)
Trial: 12666710
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine mouthrinse (15 ml, 30 seconds)
Trial: 12666710
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine mouthrinse (10 ml, 60 seconds)
Trial: 9194621
Drug: Maternal intravenous
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal intravenous magnesium sulfate therapy
Trial: 1535083
Drug: BAY u
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY u 3405 (20 mg orally 1 hour before challenges)
Trial: 3032562
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg orally
Trial: 3032562
Drug: enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 5 mg intravenously
Trial: 3032562
Drug: enalapril (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (oral and intravenous) and enalaprilat (intravenous)
Trial: 23213082
Drug: Restorative occupational
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorative occupational therapy intervention
Trial: 11158452
Drug: Early dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early dexamethasone treatment
Trial: 11158452
Drug: Delayed selective
RxNorm normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed selective treatment
Trial: 3298406
Drug: Lymphoblastoid interferon
RxNorm normalized name: interferon alfa-n1 lymphoblastoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoblastoid interferon (thrice weekly for 6 months after a 5-day induction phase)
Trial: 20556258
Drug: Platform-switched implants
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched implants (n = 75)
Trial: 20556258
Drug: Nonplatform-switched implants
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonplatform-switched implants (n = 14)
Trial: 12020739
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (360 mg)
Trial: 12020739
Drug: Ginseng (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (400 mg)
Trial: 12020739
Drug: Ginkgo/ginseng combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo/ginseng combination (960 mg)
Trial: 30624753
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 0 mg Zn/sachet
Trial: 30624753
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 5 mg Zn/sachet
Trial: 30624753
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 10 mg Zn/sachet
Trial: 30624753
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 15 mg Zn/sachet
Trial: 30624753
Drug: Comparison with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with published data on child zinc absorption
Trial: 24503952
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) 400 mg/day
Trial: 24503952
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued protease inhibitor regimen)
Trial: 22824079
Drug: S-1 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40 mg/m2 bid for 21 days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle
Trial: 22824079
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle
Trial: 19157559
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol gel forming solution once every morning
Trial: 17998079
Drug: Mixed-mode survey
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-mode survey design (phone administration followed by mail follow-up for nonresponders)
Trial: 14729431
Drug: Seropositive for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositive for IgG antibodies at baseline
Trial: 14729431
Drug: Seropositive for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositive for IgA antibodies at baseline
Trial: 14729431
Drug: Increasing anti-Chlamydia
RxNorm normalized name: Chlamydia trachomatis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing anti-Chlamydia pneumoniae antibody titers
Trial: 12078851
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5%/clindamycin phosphate 1% gel
Trial: 2952685
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1% solution
Trial: 368965
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol ointment
Trial: 368965
Drug: Ointment with
RxNorm normalized name: OINTMENT WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment with 60% DMSO
Trial: 368965
Drug: Ointment with
RxNorm normalized name: OINTMENT WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment with 5% IDU and 60% DMSO
Trial: 368965
Drug: Ointment with
RxNorm normalized name: OINTMENT WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment with 40% IDU and 60% DMSO
Trial: 25824556
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (MgSO4) 5 g in normal saline infused over 6 hours, administered 2 days before surgery, repeated the day before and during surgery.
Trial: 17298712
Drug: High monounsaturated
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High monounsaturated fat diet (HMF; 50% fat, 20% protein (67 g/d), 30% carbohydrate)
Trial: 17298712
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (HP; 40% protein (136 g/d), 30% fat, 30% carbohydrate)
Trial: 15105231
Drug: Morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 100 microg plus clonidine 60-150 microg (MC60-150)
Trial: 15105231
Drug: Morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 100 microg plus clonidine 30 microg
Trial: 9892859
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg, mane)
Trial: 9892859
Drug: Dothiepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (75 mg rising to 150 mg in the second week, nocte)
Trial: 1723772
Drug: Ro 40-5967
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40-5967 (200 mg)
Trial: 1723772
Drug: Ro 40-5967
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40-5967 (100 mg)
Trial: 1723772
Drug: Ro 40-5967
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40-5967 (all doses)
Trial: 21273900
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of triamcinolone acetonide
Trial: 21273900
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 1% procaine HCl
Trial: 21273900
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of triamcinolone acetonide and 4 ml of 1% procaine HCl
Trial: 15505867
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy with rhenium-188-DTPA-filled balloon
Trial: 9510277
Drug: Polytetrafluoroethylene Patch
RxNorm normalized name: polytetrafluoroethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytetrafluoroethylene Patch Closure (PTFE-P)
Trial: 23514767
Drug: Higher iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher iron supplement
Trial: 20142600
Drug: Pre-emptive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive treatment (skin moisturizers, sunscreen, topical steroid, doxycycline)
Trial: 20142600
Drug: Reactive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive treatment (after skin toxicity developed)
Trial: 24948702
Drug: Pre-emptive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive treatment
Trial: 11344197
Drug: human corticotropin-releasing
RxNorm normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human corticotropin-releasing hormone (hCRH)
Trial: 3548982
Drug: Diflunisal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500 mg BID, increased to 750 mg BID for non-responders)
Trial: 3548982
Drug: Naproxen (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (375 mg BID, increased to 500 mg BID for non-responders)
Trial: 29907624
Drug: Rectal douching/enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal douching/enema (RD) performed weekly or more
Trial: 24356253
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) administered twice daily according to FDA weight bands
Trial: 24356253
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) administered once daily according to FDA weight bands
Trial: 18042975
Drug: Bronchodilator groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator groups (salbutamol and ipratropium)
Trial: 15653705
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 30 mg kg(‐1) as a bolus before induction and 10 mg kg(‐1) h(‐1) by infusion
Trial: 15653705
Drug: Clonidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 3 microg kg(‐1) as a bolus before induction and 2 microg kg(‐1) h(‐1) by infusion
Trial: 10434229
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg chewable tablet of montelukast
Trial: 10434229
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg film-coated tablet of montelukast (adults)
Trial: 7788204
Drug: Fenoterol inhaled
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol inhaled 10 min before induction
Trial: 7788204
Drug: Placebo inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled 10 min before induction
Trial: 2112150
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) leuprolide acetate depot
Trial: 28185643
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T3; 1 μg/kg per body weight/dose) administered every 6 hours for 60 hours after induction of anesthesia
Trial: 22775479
Drug: Topical Xilei
RxNorm normalized name: Xilep
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical Xilei San (0.1 g/dose per day)
Trial: 22775479
Drug: Topical Xilei
RxNorm normalized name: Xilep
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical Xilei San
Trial: 11953077
Drug: Nitroglycerin patch
RxNorm normalized name: Nitroglycerin Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patch
Trial: 2132303
Drug: Polyoestradiol phosphate
RxNorm normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyoestradiol phosphate (PEP) 160 mg/month i.m.
Trial: 31915308
Drug: Mirtazapine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (dose not specified) over 28 days
Trial: 25424132
Drug: Supervised implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised implementation of an oral healthcare protocol and education
Trial: 23978872
Drug: 450 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/day UDCA
Trial: 16163627
Drug: Famciclovir 125
RxNorm normalized name: famciclovir 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 125 mg twice daily for 5 days
Trial: 16163627
Drug: Famciclovir 250
RxNorm normalized name: famciclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 250 mg twice daily for 5 days
Trial: 16163627
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg twice daily for 5 days
Trial: 12188088
Drug: Intact bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intact bovine colostrum protein powder (60 g x day(‐1))
Trial: 8979563
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (PB, PHT, SVP)
Trial: 6150121
Drug: Activated charcoal,
RxNorm normalized name: activated charcoal, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal, 50 g, given 5 min after 400 mg cimetidine + 10 mg pindolol
Trial: 29462506
Drug: LCPT (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT (extended-release tacrolimus tablets)
Trial: 27244765
Drug: Triptorelin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.1 mg (Group A)
Trial: 27244765
Drug: Triptorelin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 50 µg (Group B)
Trial: 27244765
Drug: Triptorelin 25
RxNorm normalized name: triptorelin 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 25 µg (Group C)
Trial: 25755182
Drug: Abdominal subcutaneous
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal subcutaneous fat (per SD increment) in women
Trial: 20337206
Drug: Letrozole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (5 mg daily from day 3-7 of menstrual cycle)
Trial: 20337206
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg daily from day 3-7 of menstrual cycle)
Trial: 20337206
Drug: Letrozole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (5 mg daily)
Trial: 3051880
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg daily)
Trial: 11792152
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg/day)
Trial: 7730962
Drug: Customary oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary oral hygiene care
Trial: 28889155
Drug: Ultrasound (US)‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US)‐guided transversus abdominis plane (TAP) block, 0.3 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Trial: 28889155
Drug: Ilio‐inguinal/ilio‐hypogastric (II/IH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilio‐inguinal/ilio‐hypogastric (II/IH) block, 0.7 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Trial: 28889155
Drug: Caudal block,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block, 0.5 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Trial: 19667022
Drug: Mitoxantrone induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone induction therapy followed by glatiramer acetate (GA)
Trial: 22093991
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone (2 × 15 mg for 1st postoperative 24 h; 2 × 10 mg for 2nd postoperative 24 h), paracetamol & tramadol hydrochloride tablets (8 × 1 tablet for postoperative 48 h) orally plus pethidine injection on demand (OXY group)
Trial: 22093991
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia with 0.1% ropivacaine, 0.1 µg/ml sufentanil plus injected pethidine on demand (EDA group)
Trial: 22093991
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone (OXY group)
Trial: 7793221
Drug: Propofol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0 mg.kg‐1) followed by low dose (6 mg.kg‐1.h‐1) infusion
Trial: 7793221
Drug: Propofol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0 mg.kg‐1) followed by high dose (12 mg.kg‐1.h‐1) infusion
Trial: 7793221
Drug: Methohexital (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (1.5 mg.kg‐1) followed by low dose (5 mg.kg‐1.h‐1) infusion
Trial: 7793221
Drug: Methohexital (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (1.5 mg.kg‐1) followed by high dose (10 mg.kg‐1.h‐1) infusion
Trial: 2286598
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg once daily for seven days
Trial: 2286598
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily for seven days
Trial: 7291971
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin (5000 units 8 hourly)
Trial: 29274831
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1 g) preoperatively
Trial: 18490495
Drug: Aliskiren 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 1200 mg
Trial: 18490495
Drug: Aliskiren (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (both doses)
Trial: 10485152
Drug: Insulin-dependent diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetes patients
Trial: 29898030
Drug: Topical Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Erythropoietin (EPO) - 1 mL of gel containing erythropoietin at a concentration of 4,000 IU mL‐1 applied to the donor site
Trial: 29898030
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - 2 mL of gel alone applied to the donor site
Trial: 29898030
Drug: Topical Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Erythropoietin (EPO)
Trial: 20955402
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with Arginine Butyrate administered 5 d/week for 12 weeks
Trial: 9652880
Drug: Captopril 75
RxNorm normalized name: captopril 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 75 mg/d and placebo (Group A)
Trial: 9652880
Drug: Captopril 75
RxNorm normalized name: captopril 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 75 mg/d plus losartan 12.5 mg (first dose), then 25 mg/d (Group B)
Trial: 8587088
Drug: Super Malic
RxNorm normalized name: Magnesium/Malic Acid/Niacin/Pyridoxine/Riboflavin 50 MG-200 MG-33.3 MG-16.67 MG-8.3 MG Oral Tablet [SUPER MALIC PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super Malic (200 mg malic acid and 50 mg magnesium, 3 tablets bid)
Trial: 8587088
Drug: Super Malic
RxNorm normalized name: Magnesium/Malic Acid/Niacin/Pyridoxine/Riboflavin 50 MG-200 MG-33.3 MG-16.67 MG-8.3 MG Oral Tablet [SUPER MALIC PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super Malic (up to 6 tablets bid) during open label trial
Trial: 2655501
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (1 mg)
Trial: 2655501
Drug: Intrathecal methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal methadone (1 mg)